3 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 3 |
Follow Musculoskeletal Abnormalities: new trials by email Literature Review of Musculoskeletal Abnormalities trials Research Report on Musculoskeletal Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9 Somapacitan - SGA, Turner Syndrome | Phase 3 | Active not recruiting | Novo Nordisk A/S | 47 | 2023-02-01 | 2026-08-13 |
| Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 Encaleret, Standard of Care - Autosomal Dominant Hypocalcemia (ADH) | Phase 3 | Active not recruiting | Calcilytix Therapeutics, Inc., a BridgeBio company | 67 | 2023-01-06 | 2026-07-29 |
| A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow Somapacitan, Norditropin® - SGA, Turner Syndrome, Noonan Syndrome, ISS | Phase 3 | Active not recruiting | Novo Nordisk A/S | 412 | 2022-08-10 | 2026-06-12 |
Noonan Syndrome (2) · Turner Syndrome (2) · Calcium Metabolism Disorders (1) · Hypercalciuria (1) · Hypercalciuric Hypocalcemia, Familial (1) · Hypocalcemia (1) · Hypoparathyroidism (1) · Metabolic Diseases (1) · Muscular Diseases (1) · Musculoskeletal Diseases (1) · Nephrocalcinosis (1) · Nephrolithiasis (1)
Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Endocrine System Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Male Urogenital Diseases (3) · Urogenital Diseases (3) · Cardiovascular Abnormalities (2) · Cardiovascular Diseases (2) · Chromosome Disorders (2) · Connective Tissue Diseases (2) · Craniofacial Abnormalities (2) · Disorders of Sex Development (2) · Genetic Diseases, Inborn (2) · Gonadal Disorders (2)
somapacitan (2) · Human Growth Hormone (1) · Standard of Care (1)
Novo Nordisk A/S (2) · Calcilytix Therapeutics, Inc., a BridgeBio company (1)
Netherlands (3) · United States (3) · Canada (2) · France (2) · Italy (2) · Japan (2) · Malaysia (2) · Poland (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1)